Will ethanol development hold promise for Godavari Biorefineries’ IPO success?

Wed Oct 23 08:00:14 UTC 2024: **Summary of Godavari Biorefineries Ltd’s IPO Announcement:**

1. **IPO Launch**: Godavari Biorefineries Ltd is set to launch its Initial Public Offering (IPO) consisting of a fresh issue and an offer for sale (OFS). The company will not benefit financially from the OFS.

2. **Use of Proceeds**: The funds raised from the fresh issue will be used primarily for repaying certain outstanding borrowings.

3. **Promoter Stake**: Key promoters include Samir Shantilal Somaiya and related entities, who collectively hold 81.06% of the company’s shares pre-issue.

4. **Company Profile**: Godavari Biorefineries is an ethanol-based chemical manufacturer with an installed capacity of 570 KLPD as of June 30, 2024. It ranks among India’s largest ethanol producers and has established the country’s first bio-based EVE manufacturing facility.

5. **Capacity Expansion**: The company is expanding its distillery capacity from 600 KLPD to 1,000 KLPD, receiving environmental clearance for this growth.

6. **Product Portfolio**: Their products range from bio-based chemicals and sugar to various ethanol grades and are used across numerous industries, serving notable clients like Hershey India, Hindustan Coca-Cola, and major oil companies.

7. **Financial Performance**: Although there was notable topline growth in FY23, net profit growth was minimal, with significant losses reported in Q1 FY25. Management attributes losses to operational timing and external factors such as natural calamities and government bans on ethanol production.

8. **Investment Concerns**: The IPO price reflects a P/BV ratio of 6.31, with a high PE ratio of 120 based on FY24 earnings, suggesting possible overvaluation. The company reported a low return on equity (RoE) of 5%, raising concerns about investor risks.

9. **Market Activity**: The Sensex and Nifty saw marginal increases of 0.44% and 0.45% respectively, while the stock is noted to have risen 86% from its 52-week low.

10. **Recommendation**: Due to financial inconsistencies, overvaluation, and low returns, the report advises investors to avoid participating in this IPO.